Chris Murray joined Triumvira in April 2021 as the Head of Human Resources, developing, driving, and enhancing many critical “people operations.” He brings more than 23 years of expertise in Human Resources, 7 of those years in the Biotech/Pharma industry. During his tenure, Chris has had the opportunity to manage HR for both large and small organizations, in start-up environments, and in high-volume operations across the USA and internationally.
Mr. Murray brings extensive knowledge across the full spectrum of Human Resources including Employee Relations, Payroll & Benefits Administration, Training, Organizational Development, Talent Acquisition, HR Technology, Diversity & Inclusion, and Employment Law. In his role at Triumvira, Chris oversees HR for both the USA and Canada operations.
Mr. Murray’s prior positions include Head of HR at Lonza Bio/Pharma (Houston), Director of HR at Bellicum Pharmaceuticals, and Director of HR Operations & Technology at Taysha Gene Therapies among others. He also has previous experience as a Principal Consultant serving businesses and individuals with boutique HR and business services. He received a BA in Business Management from American Intercontinental University.
Jeffrey Erickson is a life sciences executive with more than 20 years of business development, investor relations, and strategic planning experience leading numerous deals, M&A transactions and R&D collaborations. He joined Triumvira in June 2023 as Vice President of Business Development.
Prior to joining Triumvira, Mr. Erickson was Senior Director of Corporate Development at PhaseBio Pharmaceuticals, where he structured and negotiated terms for licensing and development deals and helped support the company’s commercial planning and financing activities. Before that, Mr. Erickson worked as an analyst at Reneo Capital Management, a healthcare investment fund, and held roles of increasing responsibility at Orexigen Therapeutics, Arena Pharmaceuticals, Amgen, and Amylin Pharmaceuticals. Additionally, Mr. Erickson worked on the sequencing of the human genome at the Whitehead Institute/MIT Center for Genome Research (Broad Institute). Mr. Erickson earned a B.A. in Biochemistry from the University of Pennsylvania.
Ms. Tran joined Triumvira as Senior Vice President, Finance in July 2023 with over 25 years of experience in leading finance teams for private and public biotech companies. Prior to Triumvira, Ms. Tran served as Vice President, Finance for Pardes Biosciences. Prior to Pardes, she was Vice President, Finance at Kura Oncology, Inc. and Senior Director, Finance at Halozyme Therapeutics. Ms. Tran received a B.S. in accounting from the San Diego State University and her Certified Public Accountant designation (inactive) in California.
Before joining Triumvira, Ms. Molina was most recently VP of Global Regulatory Affairs at Cell Medica, Inc in Houston, TX, for 6 years and accumulated 30 years of experience in multiple facets of product development for pharmaceutical, biotechnology, biologic, and in vitro diagnostic products, with a primary focus on regulatory affairs. In addition to regulatory affairs, her experience includes clinical and preclinical strategic planning, quality assurance, process development and manufacturing for oncology and infectious disease products.
Ms. Molina has experience leading preparation of a variety of global regulatory submissions, including INDs, NDAs, BLAs, MAAs, global CTAs, 510Ks, PMAs, orphan and Fast Track submissions, and clinical study reports. She has held management positions at both large and small corporations, including Abbott Laboratories.
Dr. Andreas Bader joined Triumvira in 2018. Dr. Bader is a seasoned biotech executive with more than 20 years of experience in oncology drug discovery and development, and business and research strategies. Previously, Dr. Bader acted as Co-Founder and CEO of Orros Biotherapeutics LLC, and as a scientific Co-Founder of Mirna Therapeutics, Inc., where he held multiple leading positions in R&D and led research programs from discovery to the completion of Phase 1 clinical trial. Prior to Mirna, Dr. Bader functioned as the Scientific Lead of the microRNA therapeutics program at Asuragen, Inc. Dr. Bader completed his post-doctoral training at The Scripps Research Institute, La Jolla, California, received his PhD in Biochemistry and his MSc degree in Biology from the University of Innsbruck, Austria.
Ms. Rill joined Triumvira as Chief Technology Officer in June 2018. Prior to Triumvira, Ms. Rill, an accomplished expert in cellular therapy manufacturing, was responsible for the design and qualification of cell & gene therapy laboratories using novel technologies, cGMP vector production facilities, core service laboratories, and translational research laboratories. In addition to her construction, project management and regulatory/QA/QC/(c)GxP knowledge, she brings extensive operational and strategic experience in cell and gene therapy, monoclonal antibody production, and protein production. Ms. Rill will oversee all North American operations for Triumvira.
Ms. Rill’s earlier positions include Vice President of Manufacturing for Cell Medica, Chief Development Officer for Opexa Therapeutics, Laboratory Director of Cell and Gene Therapy at Baylor College of Medicine (Head: Prof. Malcolm Brenner); and Lab Manager of the GMP Cell & Gene Therapy Laboratories at St. Jude Children’s Research Hospital.
Dr. Adib brings to Triumvira Immunologics over 24 years of medical oncology experience in the biotech and pharmaceutical industries, including 7 successful registrations across various hematologic as well as solid tumor maladies. Most recently, he was the founder of MariCel Clinical Consulting , LLC. Offering strategic services to the biotech industry.
Dr. Adib held multiple seats as a scientific advisory board member at several biotech companies including Imbrium therapeutics a Perdue Pharma subsidiary and a strategic consultant for advanced cell therapy programs through 1st IND at Bellicum pharmaceuticals for the BPX-601: GoCAR-T® currently in Phase I/II clinical trials for solid tumors and at KSQ for eTIL™ autologous cell therapy candidates, KSQ-001.
Past leadership roles include acting Chief Medical Officer at Rain Therapeutics advancing the clinical programs and designing clinical strategy to build the oncology portfolio leading to a successful IPO. In addition, Dr. Adib was Vice president late-stage development at Blueprint Medicines and global therapeutics Head for Solid Tumors at Baxalta, Inc., advancing the development of imalumab in various solid tumors and licensing a nano liposomal irinotecan later approved for pancreatic cancer & leading the clinical evaluation for acquiring Oncaspar from Sigma-Tau Pharmaceuticals (Leadiant Biosciences, Inc.) approved in ALL. He also led the licensing of a CD19 target CAR-T from Precision Biosciences and a PDL1, LAG3, TIM3 check point inhibitor targets from Symphogen a subsidiary of Servier. He was head of hematologic Malignancies at ARIAD leading the global clinical programs for ponatinib in CML later acquired by Takeda.
Dr. Adib has also held multiple oncology clinical development leadership positions at Aventis, Sanofi and Astellas Pharma where he advanced the development of docetaxel in prostate cancer, breast cancer and gastric cancer, enzalutamide in prostate cancer, quizartinib in AML, erlotinib in NSCLC and pancreatic cancer.
Dr. Adib obtained his medical degree from Cairo University School of Medicine, Cairo, Egypt, and completed his postgraduate oncology training at the Anglo-American Hospital Association, Cairo, Egypt and Tufts University School of Medicine– Clinical Pharmacology, Drug Development and Regulation.
Robert F. Williamson, III has been active in building biotechnology companies and shareholder value for over two decades. He currently is the President and COO of Triumvira Immunologics. Previously, he was the CBO of OncoMyx, an oncolytic virus company, and CEO of BioTheryX, a protein degradation therapeutics company, raising a $100M crossover round and preparing the company for an IPO. Prior to BioTheryX, Mr. Williamson served as CEO of both PharmAkea and ATXCo, oncology and fibrosis companies financed through a partnership with Celgene, until PharmAkea’s acquisition by Galecto and ATXCo’s acquisition by Blade Therapeutics. Prior, Mr. Williamson was CEO of Arriva Pharmaceuticals, President and COO of Eos Biotechnology, which he sold to Protein Design Labs, and COO of DoubleTwist, Inc. through its acquisition by Merck and Hitachi.
Mr. Williamson also serves as a director and adviser for foundations, private, and public companies. Notably, Mr. Williamson served as an early Director of Pharmasset, Inc., where he helped finance, grow, and advance the company into the public markets and through its acquisition by Gilead in 2011 for $11 billion. Earlier, Mr. Williamson was a partner with The Boston Consulting Group and a research assistant for the Federal Reserve Board. He received a BA in economics from Pomona College and an MBA from Stanford.
Paul Lammers, MD, MSc, joined Triumvira Immunologics as President and CEO in January 2018. Before Triumvira, Dr. Lammers served as President & CEO at Mirna Therapeutics, for which company he raised $160 million through venture capital and Federal and State government funding, as well as a public listing on NASDAQ. Previously, he served as Chief Medical Officer and Head of US Product Development for EMD Serono.
During his early industry tenure, Dr. Lammers also held various executive/senior management positions in clinical development, medical and regulatory affairs, at different pharmaceutical companies, as well as at small public and privately held biotech companies. Dr. Lammers serves as Lead Independent Director for publicly-traded Salarius Pharmaceuticals, and as Director for a private biotech company, Immunomet.